A founder-held U.S. AI + biometrics patent (US 12,109,041 B2). Frontier and on-device models, deployed inside HIPAA-aware operations. No slideware, no proof-of-concept theater, only AI running in production.
AI, operationalized
AI_CAPABILITIES
210 Digital Marketing is a healthcare-only AI implementation and AI SEO agency that designs, deploys, and governs AI for clinical and patient-facing organizations. As a HIPAA-aware and 42 CFR Part 2 fluent partner, we build AI that respects how protected and substance-use health information must be handled. Our work covers patient-facing chatbots and intake assistants, AI search and answer-engine optimization so practices surface in AI Overviews and AI Mode, content and workflow automation, and the data plumbing that connects these systems to your CRM and analytics. The future of chatbots in healthcare is not novelty automation; it is compliant, accountable, senior-built systems that route, triage, and inform without exposing your organization. Our founder holds one U.S. patent, US 12,109,041 B2. Every engagement is delivered by senior practitioners, not handed to juniors, because healthcare AI carries real compliance and clinical-trust stakes that demand operator-level judgment.
Headquartered in Eagle, Idaho, we implement healthcare AI for organizations nationwide across the United States.
What AI do you actually deploy for healthcare organizations?
We deploy patient-facing chatbots and intake assistants, AI-driven search and answer-engine optimization for visibility in AI Overviews, and content and workflow automation. Each system is built to integrate with your CRM, analytics, and existing healthcare workflows.
Is your AI implementation HIPAA-aware and 42 CFR Part 2 compliant?
Yes. We are HIPAA-aware and 42 CFR Part 2 fluent, so our AI implementations are designed around how protected health information and substance-use records must be handled. We build with compliance and patient trust as constraints from the start, not as an afterthought.
What makes 210 different from other healthcare AI implementation companies?
We have been healthcare-only since 2005, roughly 20 years, and every engagement is delivered by senior practitioners. Our founder holds one U.S. patent, US 12,109,041 B2, and is a psychologist who built and sold his own behavioral-health company.
A founder-patented AI + biometrics stack — attribution, automation, and engineering deployed inside HIPAA-eligible systems, not bolted on after the fact.
HIPAA-aware AI, deployed inside the systems that actually produce revenue.
PHI-aware by default, human-in-the-loop by design.
PHI-aware data brokering across SFTP, HL7, and FHIR. BAAs are in place before any data moves.
Vector store and de-identified RAG corpus, with provenance metadata required on every record.
Frontier-model orchestration with confidence and citation gates applied inline.
Mandatory human-in-the-loop, with licensed-clinician sign-off on any YMYL output.
CMS, API, and channel publish with a full audit log and a rollback path.
Each runs in production with PHI, human review, and BAA-backed deployment.
Conversational capture of history, insurance, and intent; routes the clinical path; answers in English or Spanish; human review on every case.
ExploreStructured extraction from clinical notes, automated packet assembly, payer-submission routing, and clinician override on every decision.
ExploreAmbient scribe plus structured SOAP synthesis with clinician sign-off; nothing unverified enters the record.
ExploreFirst-party data stitching, server-side conversions, AI creative prediction, and payer-mix-aware budget allocation.
ExploreQuantized models on clinician devices where PHI cannot leave the machine; traces to our founder's U.S. AI patent.
ExploreNative Spanish generation with cultural adaptation, not machine translation; powers hreflang and dual-schema for Hispanic-market acquisition.
ExploreOpen any practice for deliverables, staffing, and the measured outcome.
Production-grade AI inside revenue systems: intake, prior-auth automation, clinical docs, attribution. Human-in-the-loop, BAA-backed.
ExploreFirst-party data, server-side attribution, AI creative testing, conversion-grade landing pages, CRM and sales-ops to a closed-loop number.
ExploreSeventeen-phase architecture, pillar-spoke content, entity-rich schema, AI Overview citations across ChatGPT, Gemini, Claude, Perplexity.
ExploreAdmissions engineering, payer-mix optimization, clinical brand, multi-state expansion; 42 CFR Part 2 compliant.
ExploreDiligence-grade brand, provider-acquisition funnels, reimbursement-aware go-to-market, category positioning, investor narrative.
ExploreNative Spanish content engineering (not machine translation), hreflang and dual-schema, culturally-adapted creative, Hispanic patient funnels.
Explore"We did not pivot to AI. Our founder filed a U.S. AI patent and has applied statistical analysis and machine learning to healthcare data across the SPSS, TensorFlow and PyTorch eras, with regression work going back to the early 2000s."
210 Digital Marketing runs production AI inside HIPAA-covered healthcare operations, including patient intake automation, prior-authorization workflow, clinical documentation assist, attribution intelligence, on-device PHI inference, and a bilingual content engine. Each runs with human-in-the-loop review and BAA-backed deployment.
Yes. Our founder holds U.S. AI patent US 12,109,041 B2 covering AI and biometric signal interpretation, filed in 2021 and granted in 2024. It formalized statistical and machine-learning work on healthcare data across the SPSS, TensorFlow, and PyTorch eras, with regression analysis going back to the early 2000s.
Business Associate Agreements are signed before any protected health information moves. We run on-device inference where PHI cannot leave the machine, keep full audit logging on every model call, and require human-in-the-loop review on every AI workflow touching clinical content. We also support 42 CFR Part 2 operations for substance use disorder and behavioral health providers.
On-device inference runs a quantized AI model locally on a clinician device, so protected health information never leaves the machine. It matters for highest-sensitivity PHI workflows, offline clinical settings, bandwidth-constrained deployments, and jurisdiction-specific data-residency requirements. The capability traces directly to our founder's U.S. AI patent (filed 2021, issued 2024).
AI is the engineering layer beneath every practice we deliver, not a bolt-on service line. It is backed by a founder-held USPTO AI patent and senior-only delivery by 10+ year healthcare operators, with no offshore content factory.
Senior-only delivery. HIPAA-aware AI. Bilingual EN-ES. Idaho.
Book a Strategic IntakeTHE DEEP DIVE — HEALTHCARE AI
AI implementation for healthcare is the disciplined work of putting AI tools into clinical and front-office workflows — scheduling, intake, documentation, patient communication, and marketing — without breaking HIPAA, 42 CFR Part 2, or the trust patients place in you. The single most important thing to understand: there is no such thing as "HIPAA-certified AI." Compliance is not a product attribute you buy; it is an operational and architectural state you reach when a Business Associate Agreement (BAA), technical safeguards, access controls, audit evidence, retention rules, and staff behavior all line up in your specific deployment. The same model can be compliant in one clinic and a breach waiting to happen in another. 210 has worked exclusively in healthcare since 2005 — HIPAA-aware, 42 CFR Part 2 fluent, senior-only delivery, and holder of US patent 12,109,041 B2 — so we approach AI the way an operator does, at the operating level of healthcare, not as a generalist agency bolting a chatbot onto a website.
HIPAA-compliant AI means an AI deployment where a signed BAA is in place AND the administrative, physical, and technical safeguards, access rules, audit logging, retention policy, and staff behavior all hold up for your specific use case. It is a shared responsibility between the vendor and your practice, not a checkbox on a vendor's pricing page.
A vendor can hand you a BAA and still leave you exposed. A BAA is necessary but never sufficient. Before any AI tool touches protected health information (PHI), the contract should prohibit the vendor from using your prompts, outputs, or PHI to train or improve its models; name its subprocessors; commit to a breach-notification timeline; and define what happens to your data when the contract ends. You should also verify independent evidence such as SOC 2 Type II or HITRUST. A subtle point most buyers miss, and most generalist agencies cannot explain: embeddings generated from PHI are themselves PHI. They must be encrypted and access-controlled, yet many vector databases do not offer a BAA — which quietly turns an "AI search" feature into an unmanaged disclosure. The regulatory floor is also rising. The HIPAA Security Rule Notice of Proposed Rulemaking issued by HHS OCR on December 27, 2024 — the first major Security Rule update since 2013 — proposes removing the long-standing "required vs. addressable" distinction and making encryption of ePHI at rest and in transit mandatory, alongside multi-factor authentication, vulnerability scanning, and penetration testing on a fixed cadence. Those requirements apply directly to AI infrastructure. 210 treats HIPAA-compliant AI as an architecture and governance problem first and a feature second.
Implement AI one workflow at a time, starting where the data exposure is lowest and the time savings are highest: ambient documentation, scheduling, pre-visit intake, post-discharge follow-up, and billing communication. Map the PHI path for each workflow first, sign the right BAAs, then deploy — never the reverse.
Healthcare AI fails when it is bought as a product and bolted on, and it works when it is implemented as an operating change. The practical sequence is: pick a single high-friction workflow; map exactly where PHI travels and where it rests; confirm a BAA and a no-training-on-your-data clause cover that path; configure access controls and audit logging; pilot with a small group of clinicians or front-desk staff; measure against a real baseline; then expand. The 2026 use cases with the clearest return are ambient clinical documentation, automated scheduling and pre-visit intake, post-discharge follow-up, and billing and insurance communication. The adoption gap is the opportunity — many practices have not yet deployed conversational AI in these workflows, so disciplined early movers can gain real operating leverage. 210's edge here is that we have lived the operator's side of this. Our founder built and sold his own San Diego behavioral-health company, and 210 served as the marketing and AI partner behind a client's telemedicine platform that grew to a nine-figure exit — 210 was the partner, not the owner. That experience is why we plan AI rollouts around clinical reality and compliance from day one rather than retrofitting safeguards after launch.
You earn AI-search visibility (AEO/GEO) by publishing topically deep, physician-attributed content built around how patients actually describe symptoms and conditions — then proving it with an AI citation or mention-rate metric that is tracked separately from rankings and traffic. Many healthcare brands still have little or no presence in these engines.
Across ChatGPT, Gemini, Perplexity, and Google's AI Overviews, an answer is generated before any results page loads — and many healthcare brands still have little or no presence in these engines. Answer Engine Optimization (AEO) and Generative Engine Optimization (GEO) reward something traditional SEO often ignored: topical depth around the language patients use for symptoms and conditions, not just your service names. For medical content this collides directly with Google's E-E-A-T and YMYL standards, where medical pages face the highest scrutiny. The non-negotiables are a visible author byline linked to a real bio (degree, credentials, affiliations, years of practice) and content that is physician-authored or physician-reviewed — Google's guidance is explicit that YMYL content should reflect genuine expertise and authoritativeness. The vetting test serious buyers should apply to any AI/SEO agency is simple: ask to see a real client report showing an AI citation or mention-rate metric, separate from rankings and traffic. If an agency can only show impressions and clicks, it is not measuring AI visibility. 210 builds this E-E-A-T and AEO layer the compliant way — clinically credible authorship, condition-level depth, and measurement that distinguishes a citation in an AI answer from a vanity metric.
Chatbots are evolving from question-and-answer scripts into agentic AI: autonomous, multi-step systems that observe, plan, and act — verifying insurance, drafting clinical notes, working denials, and following up after discharge. Ambient clinical scribes are among the among the most widely adopted of these, and for any behavioral-health or addiction-treatment use, 42 CFR Part 2 is a second, independent compliance regime on top of HIPAA.
The 2026 inflection is the broader industry shift: AI agents that can observe, plan, and act on their own, moving past single-turn Q&A into workflow engines that handle insurance verification, claims, denial management, and documentation. Ambient clinical scribes — AI that listens to a visit and drafts the note — have reached enterprise scale and are among among the most widely adopted generative-AI use cases in health systems, freeing clinicians from after-hours charting. But for behavioral health and addiction treatment, this is exactly where most agencies get dangerous. Substance use disorder records are governed by 42 CFR Part 2, a confidentiality regime separate from HIPAA, and the Part 2 final rule's compliance deadline was February 16, 2026. The rule now permits a single patient consent covering future uses and disclosures for treatment, payment, and health care operations, aligning Part 2 more closely with HIPAA — but it remains its own legal standard with its own enforcement, which OCR began accepting complaints under on February 16, 2026. An ambient scribe or agentic intake bot that records SUD context without honoring Part 2 consent rules is a compliance failure no BAA fixes. This Part 2-plus-AI intersection is 210's sharpest advantage: our founder is a psychologist with deep behavioral-health roots, 210 is genuinely Part 2 fluent, and almost no marketing agency can speak to it with operator-grade accuracy.
Frequently asked questions
Is there such a thing as HIPAA-certified or HIPAA-compliant AI I can just buy?
No. There is no "HIPAA-certified AI" product. Compliance is an operational and architectural state, not a label. An AI tool becomes compliant only when a signed BAA, technical and physical and administrative safeguards, access controls, audit evidence, retention rules, and staff behavior all align for your specific deployment. The same model can be compliant in one clinic and non-compliant in another.
Do I need a BAA to use an AI tool with patient data, and is a BAA enough?
You need a signed Business Associate Agreement before any AI tool touches PHI, but a BAA alone is not enough. You should also require a contract clause prohibiting the vendor from training or improving its models on your prompts, outputs, or PHI, plus named subprocessors, a defined breach-notification timeline, encryption standards, data disposition at contract end, and independent evidence such as SOC 2 Type II or HITRUST.
Are AI embeddings and vector databases a hidden HIPAA risk?
Yes. Embeddings generated from PHI are themselves PHI and must be encrypted and access-controlled like any other protected data. Many vector databases used in AI features do not offer a BAA, which can turn an "AI search" or retrieval feature into an unmanaged disclosure of patient information. This is a common blind spot for generalist agencies and a specific item 210 checks for.
What AI use cases should a practice implement first?
Start where data exposure is lowest and time savings are highest: ambient clinical documentation, automated scheduling, pre-visit intake, post-discharge follow-up, and billing or insurance communication. Map the PHI path for each workflow, confirm the right BAAs and no-training clauses, pilot with a small group, measure against a real baseline, then expand one workflow at a time.
How is 42 CFR Part 2 different from HIPAA when using AI in behavioral health or addiction treatment?
42 CFR Part 2 is a separate federal confidentiality regime for substance use disorder records, independent of HIPAA. Its final rule compliance deadline was February 16, 2026, and it now allows a single patient consent for future treatment, payment, and health care operations, aligning more closely with HIPAA. But Part 2 remains its own standard with its own enforcement, so any AI tool handling SUD context — including ambient scribes and intake bots — must honor Part 2 consent rules in addition to HIPAA.
What are agentic AI and ambient clinical scribes?
Agentic AI refers to autonomous, multi-step systems that observe, plan, and act — for example verifying insurance, drafting notes, working claim denials, and handling follow-up — rather than answering one question at a time. Ambient clinical scribes are AI tools that listen to a patient visit and draft the clinical note, reducing after-hours charting. Ambient documentation is among among the most widely adopted generative-AI use cases in health systems.
How do I get my practice cited in ChatGPT, Gemini, Perplexity, and Google AI Overviews?
AI search visibility comes from Answer Engine Optimization (AEO) and Generative Engine Optimization (GEO): topically deep, physician-authored or physician-reviewed content built around how patients describe their symptoms and conditions, meeting Google's E-E-A-T and YMYL standards with a visible author byline and credentialed bio. Insist that any agency prove results with an AI citation or mention-rate metric tracked separately from rankings and traffic.
What makes 210 different for healthcare AI implementation?
210 has worked exclusively in healthcare since 2005 with senior-only delivery, is HIPAA-aware and 42 CFR Part 2 fluent, holds US patent 12,109,041 B2, and is led by a founder who is a psychologist that built and sold his own San Diego behavioral-health company. 210 was also the marketing and AI partner behind a client's telemedicine platform that reached a nine-figure exit — as the partner, not the owner. That operator and compliance depth, especially at the 42 CFR Part 2 intersection with AI, is rare among marketing agencies.
Reviewed for HIPAA and 42 CFR Part 2 accuracy by 210's senior healthcare team prior to publication.
Gonzalo D. is a psychologist who built and sold his own San Diego behavioral-health company and appeared on CNN as a youth behavioral-health advocate. He led 210 as the marketing and AI partner behind a client's telemedicine platform that reached a nine-figure exit (210 was the partner, not the owner), and is a named inventor on U.S. patent 12,109,041 B2. He is HIPAA-aware and fluent in 42 CFR Part 2 substance use disorder confidentiality requirements, with 210 working exclusively in healthcare since 2005 and delivering bilingual EN/ES, senior-only work.
Sources